Poseida Therapeutics, Inc.

NasdaqGS:PSTX 주식 보고서

시가총액: US$300.2m

Poseida Therapeutics 과거 수익 실적

과거 기준 확인 0/6

Poseida Therapeutics은 연평균 5.2%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 19.3%의 비율로 수입이 증가했습니다. 매출은 연평균 56.4%의 비율로 증가했습니다.

주요 정보

5.2%

수익 성장률

47.3%

EPS 성장률

Biotechs 산업 성장17.0%
매출 성장률56.4%
자기자본 수익률-69.7%
순이익-40.3%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%

Oct 19
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%

Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement

Sep 30

Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024

Sep 09

Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop

Aug 28
Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

May 21
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Apr 09
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement

Mar 17

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Jan 24
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

Dec 18
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Aug 13
New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Apr 17
Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech

Sep 04

Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M

Aug 11

Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B

Aug 03

Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

May 15
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

Poseida Therapeutics: Genome Engineering For Safer Cell Therapies

Oct 30

What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Mar 19
What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Jan 25
Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Dec 09

FDA lifts clinical hold on Poseida's prostate cancer cell therapy study

Nov 02

수익 및 비용 분석

Poseida Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqGS:PSTX 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 24151-61410
30 Jun 2488-113390
31 Mar 2483-109350
31 Dec 2365-123370
30 Sep 2350-131380
30 Jun 23157-29390
31 Mar 23139-45400
31 Dec 22130-64380
30 Sep 22152-29380
30 Jun 2235-142370
31 Mar 2233-145370
31 Dec 2131-125360
30 Sep 210-16334-76
30 Jun 210-15531-49
31 Mar 210-13927-23
31 Dec 200-130230
30 Sep 200-1172095
30 Jun 200-1041784
31 Mar 200-1021775
31 Dec 190-871860
30 Sep 190-761751
31 Dec 180-441031
30 Sep 180-36925
31 Dec 173-20519
31 Dec 1610-559

양질의 수익: PSTX 은(는) 현재 수익성이 없습니다.

이익 마진 증가: PSTX 은(는) 현재 수익성이 없습니다.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: PSTX 은(는) 수익성이 없지만 지난 5년 동안 연간 5.2% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 PSTX 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: PSTX 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.


자기자본 수익률

높은 ROE: PSTX 현재 수익성이 없기 때문에 마이너스 자본 수익률( -69.67% )을 갖습니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기